SynthesisInternational journal of rheumatic diseases2020
Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis.
Synthesis in International journal of rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis.International journal of rheumatic diseases · 2020Pooled it
- Serum asprosin levels in patients with rheumatoid arthritis: An exploratory cross-sectional study.Medicine · 2026Observational
- Association of 14-3-3η with Tumor Necrosis Factor (TNF-α) and Matrix Metalloproteinase-1 (MMP-1) in Rheumatoid Arthritis.Current rheumatology reviews · 2026Article
- Preconditioning of bone marrow mesenchymal stem cells with sodium hydrosulfide enhances their therapeutic potential in type II collagen-induced arthritis rat model.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Understanding the role of 14-3-3Ƞ protein in rheumatoid arthritis: from molecular dysregulation to therapeutic Redirection.Molecular biology reports · 2025Review
- Evaluation of 14-3-3eta protein as a diagnostic biomarker in the initial assessment of inflammatory arthritis.Journal of rheumatic diseases · 2025Article
- Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review.Annals of clinical biochemistry · 2025Review
- 14-3-3 Eta protein as a novel biomarker in early detection of uveitis in Egyptian juvenile idiopathic arthritis and rheumatoid arthritis patients: Diagnostic and prognostic value.Rheumatology and immunology research · 2024Article
- Temporal regulation of MDA5 inactivation by Caspase-3 dependent cleavage of 14-3-3η.PLoS pathogens · 2024Article
- Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis?Current medicinal chemistry · 2024Article
- 14-3-3η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome.Archives of Iranian medicine · 2023Article
- The Role of 14-3-3 η as a Biomarker in Rheumatoid Arthritis.Rheumatology and immunology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
aimTo evaluate the overall diagnostic performance of 14-3-3 η protein in patients with rheumatoid arthritis (RA).
methodsPubMed, EMBASE, and Web of Science were searched to acquire eligible studies. Articles published in English before 20 February 2020 were included. Quality Assessment of Diagnostic Accuracy Studies 2 was used to evaluate the risk of bias and application concern of the included articles. Pooled analysis of diagnostic indicators of 14-3-3 η protein for RA was conducted by using a random effects model. Subgroup analysis was used to explore the sources of heterogeneity. Deeks' funnel plot asymmetry test was used to evaluate for the presence of publication bias.
resultsA total of 13 studies (1554 positive and 1934 negative participants) were included. The pooled sensitivity and specificity were 0.73 (95% CI 0.71-0.75) and 0.88 (95% CI 0.87-0.90), respectively. The pooled positive/negative likelihood were 5.98 (95% CI 4.39-8.14) and 0.28 (95% CI 0.21-0.37), respectively. In addition, the pooled diagnostic odds ratio was 23.48 (95% CI 13.76-40.08) and the area under curve was 0.9245. The results of subgroup analysis indicated that ethnicity and control group might be the source of heterogeneity. The results of sensitivity analysis were stable. No significant publication bias was found.
conclusionsThe current evidence indicated that 14-3-3 η protein has moderate accuracy for the diagnosis of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.